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S286 Poster Session IIBackground: Approximately a third of all Allogeneic stem cell
transplants performed now use unrelated donors. Usually donors
have stem cells collected at centres distant from the transplant
centre. NMDP data indicates that the length of travel time and
the wait time before infusion does not affect neutrophil engraft-
ment time. A higher overall mortality was associated with bone
marrow grafts which had a combined travel and wait time
of$ 26 hours.
Method: A retrospective chart review was undertaken at Wel-
lington Hospital looking at consecutive MUD transplants be-
tween March 2004 and June 2009. Data were collected on the
disease, donor location, stem cell source, travel times, wait
time at the transplant centre before infusion, neutrophil and
platelet engraftment; and early (prior to Day +100) and overall
mortality.
Result: There were 26 consecutive MUD transplants performed
during the study period. A single cord blood transplant was ex-
cluded from analysis. 52% donor stem cells had travel times to
the transplant centre of$ 20 hours. The time between the arrival
of stem cells at the transplant centre to infusion into the patient
ranged from 1 – 42 hours. Extended travel and wait times did not
appear to impact on neutrophil or platelet recovery (median time
to neutrophil engraftment5 16 days, platelet engraftment5 20
days) or mortality.
Conclusion: The majority of collections for our centre were from
Germany. In all cases, combined travel and wait times before infu-
sions were greater than 30 hours. With the caveat of small numbers,
there appeared to be no difference in neutrophil and platelet engraft-
ment times or to early or overall mortality. In some cases there were
considerable delays between stem cells arriving at the transplant cen-
tre and infusion into the patient. Our remote location and the logis-
tics related to flight arrival times and TBI timing make this
unavoidable.345
LOW-DOSE ANTI-T-LYMPHOCYTE GLOBULIN (ATG-FRESIUS) SIGNIFI-
CANTLY REDUCES ACUTE GVHD AND NON-RELAPSE MORTALITY
(NRM) AFTER REDUCED-INTENSITY UNRELATED BMT
Ueno, N., Fuji, S., Fukuda, T., Yakushijin, K., Kurosawa, S.,
Asakura, Y., Mori, M., Hiramoto, N., Kamiyama, Y., Fukuhara, S.,
Kim, S.-W., Mori, S., Tanosaki, R., Heike, Y., Takaue, Y. National Can-
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Introduction: Unrelated HSCT with a reduced-intensity condi-
tioning regimen (RIC) is now widely performed as an alternative
to HLA-matched related HSCT. However, the optimal regimen
has not yet been well established in Japan, where peripheral blood
stem cell transplantation is not yet allowed for unrelated pairs. In
this retrospective analysis of unrelated RIC BMT, we evaluated
the feasibility of a regimen using a lower dose of rabbit ATG (Fre-
sius) and TBI.
Patients and Methods: From January 2000 to May 2009, 108
patients received unrelated BMT with a RIC regimen that in-
cluded fludarabine or cladribine plus busulfan. Additionally, 30
patients received 4 Gy TBI, 45 received 2 Gy TBI, and 33 re-
ceived lower doses of ATG (5 mg/kg, n5 20; 10 mg/kg,
n5 13). Endpoints included the probability of acute GVHD,
engraftment, NRM, overall survival (OS) and progression-free
survival (PFS).
Results: The probability of grade II-IV acute GVHD was, respec-
tively, 58%, 71%, and 17% in the 4 Gy TBI, 2 Gy TBI and ATG-
containing groups (P5 0.0002). The probability of grade III-IV
acute GVHD was, respectively, 37%, 9% and 0% in the 4 Gy
TBI, 2 Gy TBI and ATG-containing groups (P5 0.0002). There
were 7 graft failures in the ATG group (1 primary and 6 second-
ary), 1 secondary graft failure was observed in the 4 Gy group
and 1 primary graft failure was seen in the 2 Gy group. The prob-
ability of NRM at 1 year was 48% in the 4 Gy group, 17% in the
2 Gy group and 0% in the ATG group. At 2 years, this was 52% in
the 4 Gy group, 23% in the 2 Gy group and 19% in the ATG
group (P5 0.003). The probability of death due to relapse/pro-
gression at 2 years was 19% in the 4 Gy group, 36% in the 2 Gygroup and 32% in the ATG group (P5 0.32). The 2-year OS
was 40% in the 4 Gy group, 50% in the 2 Gy group and 60% in
the ATG group (P5 0.05). The 2-year PFS was 40% in the
4 Gy group, 50% in the 2 Gy group and 52% in the ATG group
(P5 0.21).
Conclusion: A lower dose of ATG-Fresius (5-10 mg/kg) signifi-
cantly reduced the risk of acute GVHD and NRM compared to
low-dose TBI after unrelated BMT in a RIC setting, despite an as-
sociated higher rate of secondary graft failure. These findings will
need to be confirmed in a larger prospective randomized-
controlled trial.346
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Background: For many maligant diseases, median age at diagno-
sis is around the sixth decade of life, precluding myeloablative
ALLO. RIC-ALLO is less toxic and has been performed in el-
derly pts, mainly affected by acute leukemia. Prognostic indexes
seem to predict treatment related mortality (TRM) and overall
survival (OS).
Patients and methods: From 2001 and 2008, 63 pts older than 60
years (median age 63 y, range 60-70) received RIC-ALLO. Dis-
eases were: acute myeloid leukemia 45%, and chronic lymphopro-
liferative diseases 54%. Disease status at RIC-ALLO was: complete
remission 54%, partial remission 16%, and active disease 30%.
RIC consisted of fludarabine-based with thymoglobulin 64%, or
low-dose TBI-based 36%. Donors were: HLAid sibling 73%,
matched unrelated 21%, and cord blood 6%. Three prognostic
scores were evaluated.
Results: The median follow-up was 22 months. The 2-y OS and
PFS were 66.8% (IC95; 55.5-80.4) and 52.4% (IC95:39.5-69.5), re-
spectively. Grade II-IV acute graft versus host disease (aGVHD) and
chronic GVHD (cGVHD) incidence were 49% and 43%, respec-
tively. Early infections were fever of unknown origin in 42% of
pts, bacterial infection in 6 cases, pneumonia in 8, and viral infections
in 14. The early infection-related mortality was null. Late infections
were bacterial in 3 cases, pneumonia in 1, viral infections in 6, and
candidemia in 1. Seven pts died from late infective complications.
Overall, the cause of death was toxicities in 18 pts and disease pro-
gression in 6 pts. The 100-d and 1-y TRM were 6% and 24%, re-
spectively.
In univariate analysis, HCT-CI, EBMT score, and PAM score did
not influence TRM or OS. Furthermore, age (60-65 vs 66-70) was
not related to TRM. Only severe aGVHD was predictive.
Conclusions: The aim of this retrospective study was to assess
if TRM was excessively high in elderly pts, after ALLO-RIC.
A secondary objective was to evaluate if any of the current
prognostic indexes could predict TRM and OS in this peculiar
population. TRM was acceptable and not different when com-
pared to younger pts as reported in literature. Furthermore,
neithe prognostic index nor age help segregating a group of
pts with higher TRM limiting their value for treatment decision
in this situation.347
ABSOLUTE NEUTROPHIL COUNT LESS THAN 0.2  109/L ON DAY SIX-
TEEN POST-TRANSPLANT MARKEDLY INCREASES THE RISK OF GRAFT
FAILURE
Olsson, R., Remberger, M., Ringden, O. Karolinska University Hospital,
Stockholm, Sweden
Following allogeneic hematopoietic stem cell transplantation
(HSCT) graft failure is a major complication, which markedly
